Cargando…

Evaluation of the QIAstat-Dx RP2.0 and the BioFire FilmArray RP2.1 for the Rapid Detection of Respiratory Pathogens Including SARS-CoV-2

Point-of-care syndromic panels allow for simultaneous and rapid detection of respiratory pathogens from nasopharyngeal swabs. The clinical performance of the QIAstat-Dx Respiratory SARS-CoV-2 panel RP2.0 (QIAstat-Dx RP2.0) and the BioFire FilmArray Respiratory panel RP2.1 (BioFire RP2.1) was evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassidy, Hayley, van Genne, Mart, Lizarazo-Forero, Erley, Niesters, Hubert G. M., Gard, Lilli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989387/
https://www.ncbi.nlm.nih.gov/pubmed/35401449
http://dx.doi.org/10.3389/fmicb.2022.854209
_version_ 1784683161163137024
author Cassidy, Hayley
van Genne, Mart
Lizarazo-Forero, Erley
Niesters, Hubert G. M.
Gard, Lilli
author_facet Cassidy, Hayley
van Genne, Mart
Lizarazo-Forero, Erley
Niesters, Hubert G. M.
Gard, Lilli
author_sort Cassidy, Hayley
collection PubMed
description Point-of-care syndromic panels allow for simultaneous and rapid detection of respiratory pathogens from nasopharyngeal swabs. The clinical performance of the QIAstat-Dx Respiratory SARS-CoV-2 panel RP2.0 (QIAstat-Dx RP2.0) and the BioFire FilmArray Respiratory panel RP2.1 (BioFire RP2.1) was evaluated for the detection of SARS-CoV-2 and other common respiratory pathogens. A total of 137 patient samples were retrospectively selected based on emergency department admission, along with 33 SARS-CoV-2 positive samples tested using a WHO laboratory developed test. The limit of detection for SARS-CoV-2 was initially evaluated for both platforms. The QIAstat-Dx RP2.0 detected SARS-CoV-2 at 500 copies/mL and had a positive percent agreement (PPA) of 85%. The BioFire RP2.1 detected SARS-CoV-2 at 50 copies/mL and had a PPA of 97%. Both platforms showed a negative percent agreement of 100% for SARS-CoV-2. Evaluation of analytical specificity from a range of common respiratory targets showed a similar performance between each platform. The QIAstat-Dx RP2.0 had an overall PPA of 82% (67–100%) in clinical samples, with differences in sensitivity depending on the respiratory target. Both platforms can be used to detect acute cases of SARS-CoV-2. While the QIAstat-Dx RP2.0 is suitable for detecting respiratory viruses within a clinical range, it has less analytical and clinical sensitivity for SARS-CoV-2 compared to the BioFire RP2.1.
format Online
Article
Text
id pubmed-8989387
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89893872022-04-08 Evaluation of the QIAstat-Dx RP2.0 and the BioFire FilmArray RP2.1 for the Rapid Detection of Respiratory Pathogens Including SARS-CoV-2 Cassidy, Hayley van Genne, Mart Lizarazo-Forero, Erley Niesters, Hubert G. M. Gard, Lilli Front Microbiol Microbiology Point-of-care syndromic panels allow for simultaneous and rapid detection of respiratory pathogens from nasopharyngeal swabs. The clinical performance of the QIAstat-Dx Respiratory SARS-CoV-2 panel RP2.0 (QIAstat-Dx RP2.0) and the BioFire FilmArray Respiratory panel RP2.1 (BioFire RP2.1) was evaluated for the detection of SARS-CoV-2 and other common respiratory pathogens. A total of 137 patient samples were retrospectively selected based on emergency department admission, along with 33 SARS-CoV-2 positive samples tested using a WHO laboratory developed test. The limit of detection for SARS-CoV-2 was initially evaluated for both platforms. The QIAstat-Dx RP2.0 detected SARS-CoV-2 at 500 copies/mL and had a positive percent agreement (PPA) of 85%. The BioFire RP2.1 detected SARS-CoV-2 at 50 copies/mL and had a PPA of 97%. Both platforms showed a negative percent agreement of 100% for SARS-CoV-2. Evaluation of analytical specificity from a range of common respiratory targets showed a similar performance between each platform. The QIAstat-Dx RP2.0 had an overall PPA of 82% (67–100%) in clinical samples, with differences in sensitivity depending on the respiratory target. Both platforms can be used to detect acute cases of SARS-CoV-2. While the QIAstat-Dx RP2.0 is suitable for detecting respiratory viruses within a clinical range, it has less analytical and clinical sensitivity for SARS-CoV-2 compared to the BioFire RP2.1. Frontiers Media S.A. 2022-03-24 /pmc/articles/PMC8989387/ /pubmed/35401449 http://dx.doi.org/10.3389/fmicb.2022.854209 Text en Copyright © 2022 Cassidy, van Genne, Lizarazo-Forero, Niesters and Gard. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Cassidy, Hayley
van Genne, Mart
Lizarazo-Forero, Erley
Niesters, Hubert G. M.
Gard, Lilli
Evaluation of the QIAstat-Dx RP2.0 and the BioFire FilmArray RP2.1 for the Rapid Detection of Respiratory Pathogens Including SARS-CoV-2
title Evaluation of the QIAstat-Dx RP2.0 and the BioFire FilmArray RP2.1 for the Rapid Detection of Respiratory Pathogens Including SARS-CoV-2
title_full Evaluation of the QIAstat-Dx RP2.0 and the BioFire FilmArray RP2.1 for the Rapid Detection of Respiratory Pathogens Including SARS-CoV-2
title_fullStr Evaluation of the QIAstat-Dx RP2.0 and the BioFire FilmArray RP2.1 for the Rapid Detection of Respiratory Pathogens Including SARS-CoV-2
title_full_unstemmed Evaluation of the QIAstat-Dx RP2.0 and the BioFire FilmArray RP2.1 for the Rapid Detection of Respiratory Pathogens Including SARS-CoV-2
title_short Evaluation of the QIAstat-Dx RP2.0 and the BioFire FilmArray RP2.1 for the Rapid Detection of Respiratory Pathogens Including SARS-CoV-2
title_sort evaluation of the qiastat-dx rp2.0 and the biofire filmarray rp2.1 for the rapid detection of respiratory pathogens including sars-cov-2
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989387/
https://www.ncbi.nlm.nih.gov/pubmed/35401449
http://dx.doi.org/10.3389/fmicb.2022.854209
work_keys_str_mv AT cassidyhayley evaluationoftheqiastatdxrp20andthebiofirefilmarrayrp21fortherapiddetectionofrespiratorypathogensincludingsarscov2
AT vangennemart evaluationoftheqiastatdxrp20andthebiofirefilmarrayrp21fortherapiddetectionofrespiratorypathogensincludingsarscov2
AT lizarazoforeroerley evaluationoftheqiastatdxrp20andthebiofirefilmarrayrp21fortherapiddetectionofrespiratorypathogensincludingsarscov2
AT niestershubertgm evaluationoftheqiastatdxrp20andthebiofirefilmarrayrp21fortherapiddetectionofrespiratorypathogensincludingsarscov2
AT gardlilli evaluationoftheqiastatdxrp20andthebiofirefilmarrayrp21fortherapiddetectionofrespiratorypathogensincludingsarscov2